Cardiac stem cell therapy: Checkered past, promising future?

Slides:



Advertisements
Similar presentations
Bone Marrow-Derived Cell Therapy Stimulates Endogenous Cardiomyocyte Progenitors and Promotes Cardiac Repair Francesco S. Loffredo, Matthew L. Steinhauser,
Advertisements

Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Manuel J. Antunes, MD, PhD, DSc 
How do cells talk to each other
“Lead from the front”: Participative leadership
Personalized cardiac surgery: Can noninvasive flow imaging lead to individualized resection strategies for bicuspid aortopathy?  Nicholas D. Andersen,
Pulmonary hypertension in valve disease: A beast of the past?
Intrinsic cardiac stem cells are essential for regeneration
Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 
Bone Marrow-Derived Cell Therapy Stimulates Endogenous Cardiomyocyte Progenitors and Promotes Cardiac Repair  Francesco S. Loffredo, Matthew L. Steinhauser,
Devendra K. Agrawal, PhD, MBA, Chandra S. Boosani, PhD 
Form ever follows function
William M. DeCampli, MD, PhD 
Application of a neuroscience research model to study neuroprotection in children with congenital heart disease  Nobuyuki Ishibashi, MD, Richard A. Jonas,
Philippe Menasché, MD, PhD 
The use of vancomycin paste to reduce sternal wound infections after cardiac surgery— why is this still a “sticky” subject  Harold L. Lazar, MD  The Journal.
New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum  Martin Czerny, MD, MBA  The Journal.
Surgeons, valve repair in severely unbalanced atrioventricular septal defect, and the emperor's new clothes  David M. Overman, MD  The Journal of Thoracic.
Bigger The Journal of Thoracic and Cardiovascular Surgery
Commentary: Rejuvenation of “broken heart” with bioengineered gel
The lord of the rings  Antonio Miceli, MD, PhD 
The variability of the mitral valve anatomy and terminology
Aditya K. Kaza, MD  The Journal of Thoracic and Cardiovascular Surgery 
Juan N. Pulido, MD  The Journal of Thoracic and Cardiovascular Surgery 
Michael Mack, MD, David Taggart, MD 
Innovation and science: The future of valve design
It's not “just a shunt” but sometimes it should be…
A first start for lung transplantation?
Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies  J. James Edelman, MBBS(Hons), PhD, Vinod H. Thourani,
Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005  Scott D. Barnett, PhD,
Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD 
Michael Lanuti, MD  The Journal of Thoracic and Cardiovascular Surgery 
Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD 
Niv Ad, MD, Lawrence M. Wei, MD 
Guidelines should bother us, not comfort us
The Journal of Thoracic and Cardiovascular Surgery
Instrumental variable methods in clinical research
The Ross procedure: Time to reevaluate the guidelines
Passing the torch The Journal of Thoracic and Cardiovascular Surgery
Biomaterials for heart valve replacement: Conjectures and refutations
Shunt right or left? Decision 2016
Zhi Cui, MSc, Ren-Ke Li, MD, PhD 
Warfarin or aspirin after mitral valve repair: Why work harder?
Cardiac Stem Cell Therapy and the Promise of Heart Regeneration
First nights, the adrenal axis, and steroids
The origins of open heart surgery at the University of Minnesota 1951 to 1956  Richard A. DeWall, MD  The Journal of Thoracic and Cardiovascular Surgery 
Jeffrey H. Shuhaiber, MD, Jeff Moore, MS, David B. Dyke, MD 
The Journal of Thoracic and Cardiovascular Surgery
Discussion The Journal of Thoracic and Cardiovascular Surgery
A call for standardized end point definitions regarding outcomes of extracorporeal membrane oxygenation  John J. Squiers, BSE, Brian Lima, MD, J. Michael.
Tissue valve, nitinol stent, or storage solution
The future of cardiac surgery training: A survival guide
Apparently, size matters…in congenital heart disease and brain injury
The continuing challenge of congenital heart disease in China
Between a rock and a hard place
The Robin Hood principle in the treatment of congenital heart disease: Taking technologic developments intended for adults and using it in kids  Paul.
After neoadjuvant chemoradiation therapy, predicted pulmonary function may be reduced by 10%  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular.
Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD 
“The more things change…”: The challenges ahead
Evaluating the best approach to treatment of aortic stenosis: The jury is still out  Glen B. Taksler, PhD  The Journal of Thoracic and Cardiovascular Surgery 
First in line for robotic surgery: Would you want to know?
Should heart transplantation be considered as a treatment option for patients aged 70 years and older?  Jeffrey A Morgan, MD, Ranjit John, MD, Donna M.
Ryan R. Davies, MD  The Journal of Thoracic and Cardiovascular Surgery 
More than vital: Who bears the burden?
Respect the aorta The Journal of Thoracic and Cardiovascular Surgery
Perioperative renal function and thoracoabdominal aneurysm repair: Where do we go from here?  Leonard N. Girardi, MD  The Journal of Thoracic and Cardiovascular.
Of mice and men… The Journal of Thoracic and Cardiovascular Surgery
Did you like Terminator 3 better than Terminator 2
Zone zero thoracic endovascular aortic repair is all about “location, location, location”  Kevin L. Greason, MD  The Journal of Thoracic and Cardiovascular.
Presentation transcript:

Cardiac stem cell therapy: Checkered past, promising future? John J. Squiers, BSE, Kelley A. Hutcheson, MD, Jeffrey E. Thatcher, PhD, J. Michael DiMaio, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 148, Issue 6, Pages 3188-3193 (December 2014) DOI: 10.1016/j.jtcvs.2014.10.077 Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Proposed mechanisms for cardiac regeneration. Therapeutic effects of stem cells likely promote some or all of these innate pathways in the treatment of cardiac disease. (1) Paracrine factors promote proliferation of cardiomyocytes. (2) Progenitor cells activate and differentiate into cardiomyocytes. (3) Mature cardiomyocytes dedifferentiate to reenter the cell cycle and proliferate into new cardiomyocytes. (4) Activated epicardium stimulates angiogenesis and/or proliferation of cardiomyocytes. (Figure adapted from Cell Stem Cell, Vol. 12, Garbern JC, Lee RT, Cardiac stem cell therapy and the promise of heart regeneration, p. 692, Copyright 2013, with permission from Elsevier.18) The Journal of Thoracic and Cardiovascular Surgery 2014 148, 3188-3193DOI: (10.1016/j.jtcvs.2014.10.077) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Approaches to cardiac regeneration in heart disease. In addition to (1) stem cell delivery, several other related methods may prove to be effective therapies. (2) Tissue engineering combines cells with mechanical support and adjunctive biomaterials that promote survival. (3) Paracrine factors may be isolated from stem cell cultures and delivered as small molecules to promote repair and regeneration. (4) Noncardiomyocytes may be reprogrammed via the delivery of viruses, small molecules, or microRNAs. All of these mechanisms may promote one or more of the pathways for cardiac regeneration described in Figure 1. (Figure adapted with permission.18) The Journal of Thoracic and Cardiovascular Surgery 2014 148, 3188-3193DOI: (10.1016/j.jtcvs.2014.10.077) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions